CD8A and neoplasm: More recently in patients treated with anti-PD-1 antibodies, frequencies of classical monocytes in the periphery[11] or a reinvigoration of circulating exhausted, Ki65+PD-1+CD8+ T-cells in conjunction with tumor burden were recently suggested as measures to predict poor clinical responses[12].